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A multifaceted approach
to modeling the immune response
in tuberculosis
Simeone Marino,1 Jennifer J. Linderman2 and Denise E. Kirschner1∗
Tuberculosis (TB) is a deadly infectious disease caused by Mycobacterium
tuberculosis (Mtb). No available vaccine is reliable and, although treatment exists,
approximately 2 million people still die each year. The hallmark of TB infection is
the granuloma, a self-organizing structure of immune cells forming in the lung and
lymph nodes in response to bacterial invasion. Protective immune mechanisms
play a role in granuloma formation and maintenance; these act over different
time/length scales (e.g., molecular, cellular, and tissue scales). The significance of
specific immune factors in determining disease outcome is still poorly understood,
despite incredible efforts to establish several animal systems to track infection
progression and granuloma formation. Mathematical and computational modeling
approaches have recently been applied to address open questions regarding
host–pathogen interaction dynamics, including the immune response to Mtb
infection and TB granuloma formation. This provides a unique opportunity to
identify factors that are crucial to a successful outcome of infection in humans.
These modeling tools not only offer an additional avenue for exploring immune
dynamics at multiple biological scales but also complement and extend knowledge
gained via experimental tools. We review recent modeling efforts in capturing
the immune response to Mtb, emphasizing the importance of a multiorgan and
multiscale approach that has tuneable resolution. Together with experimentation,
systems biology has begun to unravel key factors driving granuloma formation
and protective immune response in TB.  2010 John Wiley & Sons, Inc. WIREs Syst Biol Med
2011 3 479–489 DOI: 10.1002/wsbm.131
INTRODUCTION
Tuberculosis (TB) is a deadly infectious disease inhumans caused by the bacteria Mycobacterium
tuberculosis (Mtb).1 An estimated 2 billion people,
or one third of the world’s population, are infected
with Mtb, and approximately 2 million people died
of TB in 2008. A unique feature of Mtb is its ability
to persist in the infected host during a latent clinical
state. About 90% of those infected with Mtb have
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asymptomatic, latent TB infection (sometimes called
LTBI) with a 10% lifetime chance of progressing to
TB disease (or active TB).1,2 If untreated, the death
rate for active TB is more than 50%.2 In addition, the
presence of human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) increases
the risk of reactivation of latent TB to 10% per
year. Antibiotics reduce the risk of reactivation, but
may not lead to cure. A vaccine does exist (not used in
the United States or United Kingdom) but the efficacy
is variable at best.3 Thus, there is a global urgency to
understand this disease ranging from the epidemiology
to genetic levels. This article briefly summarizes some
of the successes that systems biology approaches, in
particular mathematical and computational modeling,
have had on exploring the within-host dynamics of
this world health problem.
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IMMUNOBIOLOGY
AND PATHOGENESIS OF TB
When considering the dynamics of an infectious dis-
ease, there are many perspectives of interest, e.g., how
it spreads through a population (epidemiology), the
dynamics of the bacterial genetics in different portions
of the world, or how the host and pathogen interact.
Although we and others have explored TB from these
and other perspectives,4–6 our focus here will be to
review studies exploring the host immune response to
infection with Mtb. The immunological processes by
which the host controls this infection are incompletely
understood. Mtb is a small nonmotile bacterium
that primarily infects the lungs in adult humans. TB
infection begins when the mycobacteria reach the
pulmonary alveoli, where they invade and replicate
within phagocytic cells termed macrophages.1,7 Mtb
divides every 16–24 h, an extremely slow rate com-
pared to typical bacteria, which divide on the order of
minutes.8 Mtb has evolved ways to evade many pro-
tective host immune mechanisms; as a consequence,
Mtb is able to multiply almost unchecked within a
resting macrophage. Bacteria are also internalized by
another phagocytic cell type, dendritic cells (DCs), at
the site of infection; these cells are less permissive for
Mtb replication and are specialized for transporting
bacteria to local, draining lymph nodes (LNs) to initi-
ate T-cell priming and an adaptive immune response
by the host. This response is required to contain infec-
tion, but is unable to clear it. The failure to clear
bacteria elicits a unique immune response at the site
of infection with the appearance of granuloma, the
hallmark of Mtb infection.
FIGURE 1 | Example of a typical granuloma. Note: the letter c
denotes the central necrotic core and infected macrophages surrounded
by a rim of lymphocytes (letter h).11,12
A granuloma appears as a spherical collection
of macrophages, T cells, B cells, and other immune
cells with the goal of immunologically restraining and
physically containing bacterial infection (Figure 1).
The typical spatial arrangement of cells is a ring of
T cells surrounding a core of infected macrophages
(Box 1). Granulomas form in response to a cascade
of cytokine and chemokine signals9 at the site of
infection. Initially they form in the lungs, but later
can be observed in LNs as well. To complicate
matters, there are various types of human (primate)
TB granulomas (caseous, necrotic, fibrotic, etc.)
and ranges in between these.10 Many questions
regarding the form and function of granuloma
BOX 1
IMMUNOLOGY TERMINOLOGY
Monocyte: Cell produced in bone marrow that
circulates throughout the bloodstream. Mono-
cytes leave the bloodstream in response to
infection and inflammation, and differentiate
into macrophages or DCs.
Macrophage: Functions as a patrol cell and
engulfs and kills foreign infectious invaders.
Macrophages also stimulate T cells to destroy
these invaders.
DC: Cell that functions as part of the adap-
tive immune system. DCs are called antigen-
presenting cells (APCs) because of their ability
to present antigens to B and T cells. Antigen
presentation helps T and B cells to recognize
and respond to pathogens.
T cell: Type of lymphocyte that helps to orches-
trate the immune system by killing pathogens
and producing or helping to produce cytokines
and chemokines.
B cell: Type of lymphocyte that produces anti-
bodies that can bind to antigens.
Antigen: A-molecule that is recognized by the
immune system as a bacterium or virus.
Cytokines: (e.g., Interferon-γ (IFN-γ ), inter-
leukin (IL)-12, tumor necrosis factor (TNF), and
IL-10): molecules produced by cells. Cytokines
interact with cells of the immune system to
regulate the body’s response to disease and
infection.
Chemokines: Molecules manufactured by cells
and tissues that stimulate movement of
immune system cells to the area where the
chemokine is produced.
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remain unanswered, yet granulomas remain as the
central player to understanding prevention, treatment,
and therapy for TB. Ultimately, the formation and
maintenance of ‘good’ or ‘working’ granuloma are
essential for control of Mtb infection. However, what
defines ‘good’ is not known.
Animal Models of Tuberculosis
Mtb infects most mammals. There are several
established animal models for Mtb, including mice,
zebra fish, guinea pigs, rabbits, and monkeys.13
However, immunologic reagents are only readily
available for mice and non-human primates (NHPs).
Mice are most commonly used, and the availability of
genetically identical and engineered mice has proven
invaluable in addressing the roles of various cells
and cytokines in control of infection. Two limitations
to the mouse model are the lack of latent infection
(infection is chronic and progressive in mice) and
the pathology: mouse granulomas are not similar in
structure to human granulomas. NHPs are similar
to humans in almost all aspects, with active TB,
latent infection, and reactivation TB observed, as
well as pathology and granulomas that are identical
to humans.14,15 The immunologic reagents available
for monkeys allow one to obtain quantitative and
qualitative data on cell populations and functions in
the lungs and LNs.10,11,14,15 However, the peculiar
slow progression of TB in NHPs (and humans) makes
comprehensive data collection particularly difficult
(and expensive) for scientists. Studies in animal
models and some human data have identified various
necessary immune factors important in control of
Mtb infection, but sufficient conditions have yet to be
uncovered. A protective immune response requires
priming and activation of antigen-specific CD4+
and CD8+ T cells, production of chemokines to
impact recruitment of cells to the infection site,
production of cytokines (e.g., IFN-γ , IL-12, TNF,
IL-10) some of whose role is to activate macrophages,
and macrophage effector molecules that kill bacteria
(such as nitric oxide). These factors all comprise the
granuloma, but the role of spatial information within
granuloma for these effector cells and molecules is
not currently available. Yet, it is likely the balance,
location, and concentrations of these and numerous
other factors within the granuloma that dictate the
outcome of infection and disease.
WHAT CAN SYSTEMS BIOLOGY
DO FOR TB RESEARCH?
Experimental biology has and will continue to be
a successful and necessary approach to exploring
infection with Mtb and other pathogens. However,
many questions in TB remain unanswered: Which
collection of immune factors is responsible for
determining whether an individual develops active
TB or latent infection? Where is latent infection
established and where does it reactivate? What events
occur in the LN that affect control at the level of the
lung, and vice versa, and how do these physiological
compartments communicate? What factors affect
timing of initiation of the immune response in the LN
and lung? What new approaches for treatment and
control might be useful? Difficulties in approaching
these questions experimentally include the number
and expense of experiments required to fully explore
all these interacting factors and various outcomes,
the time required to do experiments in the most
relevant animal system (the NHP), and the difficulty
in integrating data from multiple experiments and
from experiments aimed at various organs and at
various length (molecular, cellular, tissue, organism,
population) and time scales (e.g., seconds to lifetimes)
into a comprehensive view. For example, molecular
data on TNF binding over a period of minutes,
granuloma formation over a period of days (mice)
to weeks (NHP), T-cell priming in the LN (days),
and cellular trafficking among multiple organs are all
necessary components of understanding granuloma
formation and ultimately the immune response to
Mtb. While there is no ‘standard dataset’ available
for model development, numerous types of data
are available in the literature. Some of these are
summarized in Table 1. Using a systems biology
approach, data from both animal and computational
systems can be integrated and synthesized to
explore a complex biological system and address
relevant questions. One goal of this approach is to
create a computational model system that reflects
human biology, providing an opportunity to perform
experiments that are impractical or not feasible in vivo
or in vitro as well as generate testable hypotheses.
A Systems Biology Approach
to Understanding Immunity to Mtb
We believe that for the study of the immune response
during Mtb infection, a multiorgan (compartment)
and multiscale quantitative approach is necessary
to capture the unique, complex, and interdependent
interactions between Mtb and the host and to allow
us to integrate information across length and time
scales. A general paradigm for understanding the
immune response during Mtb infection and guiding
the development of a computational framework is
shown in Figure 2 and Table 2.
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TABLE 1 Experimental Data Availability Based on Scale/Organ Modeled in Tuberculosis (TB) Infection
Scale/Organ Data Available Techniques Data Not Available
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FIGURE 2 | Multiscale, multicompartment view of the immune response to Mycobacterium tuberculosis (Mtb) infection. Mtb introduced into the
lung (left side of figure) is taken up by dendritic cells (DCs) and macrophages (Mφs). DCs travel through the lymphatics to a draining lymph node (LN)
bringing bacteria with them. In the LN, display of peptide-major histocompatibility complexes (pMHCs) by DCs [antigen-presenting cells (APCs)] leads
to T cell priming. These cells travel to the lung via blood. Granulomas form in the lung and later, LNs (not shown). In both the lung and LN, molecular
events (e.g., pMHC binding, IL-10, and TNF receptor binding) influence cell behavior (e.g., display of pMHC complexes, cell survival, or activation) and
cell behavior influences tissue-level events (e.g., T-cell priming and granuloma formation). Within a granuloma, T cells secrete cytokines such as
IFN-γ , which activates macrophages to destroy the bacteria with which they are infected.16 Cytotoxic T cells can also directly kill infected cells, by
secreting perforin and granulysin.7 This leads to inhibition or killing of bacilli as well. Another feature of the granuloma in primates is the extensive
cell death within the tissue, called necrosis, that develops in the center of the granuloma.17 Importantly, bacteria are not always eliminated within
the granuloma, but can become dormant, resulting in a latent infection.1 Information flows both ‘bottom-up’ and ‘top-down’ (orange arrows) and ‘to
and from’ compartments (blue arrows).
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TABLE 2 Some Published Models Relevant to Understanding the Immune Response During Tuberculosis (TB)
Model Category Biology
Biological
Scale Time Scale Length Scale Model Type References
Lymph node models Peptide-MHC binding Molecular 10−1–102
seconds
























10−3–10−2 m Stochastic, discrete
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10−3 m Stochastic, discrete
(ABM)
30–32






LN to other organ models Organ/body 105–106
seconds




ABM, agent-based model; APC, antigen-presenting cell; LN, lymph node; MHC, major histocompatibility complex; ODE, ordinary differential equation; PDE,
partial differential equation; TNF, tumor necrosis factor.
Two important aspects of model development
are highlighted in Figure 2. First, biological processes
that are relevant to the immune response occur at
different length scales; molecular, cellular, and tissue
level scales are shown. Thus, models that include
relevant details at multiple scales are important.
Models developed and validated with experimental
data at individual physiological scales are then linked
to form a multiscale model and allow information
to flow in particular directions. If the results from
a model developed at the smallest scale are passed
to the model developed at the next larger scale,
the information flow is ‘bottom-up’. This can be
performed in various ways: the large-scale model
may contain the entire small-scale model, e.g., or
may simply use a parameter that is calculated in
the small-scale model. Alternatively, the linking may
also need to incorporate information flow that is
‘top-down’ if changes at larger scales affect behavior
at smaller scales. Analysis can begin at any scale
(the ‘middle-out’ approach, as pointed out by the
Nobel laureate Sydney Brenner): ‘Analysis must start
somewhere, but it does not really matter where. In
the best of all systems biological world, we will
eventually meet up, anyway’.46 The multiscale model
allows the relevance of events at that one scale
to be observed at higher or lower scales as well.
Second, models need to incorporate events occurring
in both the lung and the draining LN, necessitating
a multiorgan (compartment) model. Indeed, it is
likely that the movement of cells between these
compartments determines the speed and efficiency of
an immune response.
Importantly, models developed should have
tuneable resolution, by which we mean the ability
to fine-grain or coarse-grain model components at
will. For example, to answer questions about how a
particular cytokine’s binding kinetics affect granuloma
formation, immune system models that explicitly
include molecular processes involving this cytokine are
most useful, but those models do not need extensive
detail in the LN compartment and a relatively coarse-
grained treatment there may suffice. As models are
often used to answer different questions at different
times, then the accessibility to a model that allows for
fine graining in some scale(s) of interest and coarse
graining in others is desired. In addition, such tuneable
resolution yields some computational assistance as
well: it can improve debugging, increase the speed of
computation, and assist in analysis.
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LESSONS LEARNED FROM DIFFERENT
MODELS AIMED AT UNDERSTANDING
THE IMMUNE RESPONSE DURING TB
Over the past decade, we have developed a series
of mathematical and computational models in an
effort to qualitatively and quantitatively characterize
the immune response to Mtb infection in the
lung,29–31,33–37 and in the lung and LN (Box 2).40–42
Table 2 summarizes our work and the work of
others in this area. In addition, we have integrated
experimental data into the development and testing of




Differential equations (DEs): A system of
mathematical equation usually describing a
deterministic relation of some continuously
varying quantities (modeled by functions) and
their rates of change in space and/or time
(expressed as derivatives). There are two major
types: ordinary differential equations (ODEs)
and partial differential equations (PDEs).
Agent-based model (ABM): A class of com-
putational models for simulating the actions
and interactions of autonomous agents (either
individual or collective entities) in a hetero-
geneous environment where possibly global,
system-wide dynamics and patterns emerge
from the local, likely stochastic, individual-level
interactions.
Hybrid model: A representation in which
multiple types of mathematical models are used
simultaneously to describe a system (ODE, PDE,
ABM, etc.)
Multiscale model: A model that allows for
explicit consideration of events at a variety of
length and/or time scales.
Multicompartment model: A model that allows
for variables to be allocated in different
environments that may correspond to different
organs or tissues (compartments may each also
have multiple scales of interest). Each of the
above representations can be represented as a
compartmental model.
Tuneable resolution: A model that includes the
ability to fine grain or coarse grain particular
submodels ‘at will’.
regarding mechanisms, dynamics, and data that are
currently open questions for TB researchers. We will
focus on a few studies to highlight key findings
that different studies reveal, while emphasizing the
importance of each approach.
Single-Organ Models
The past 20 years saw a boom in the use of
mathematical models to study within-host–pathogen
interactions; most of these models explore viruses such
as HIV-1/AIDS and hepatitis C interacting with the
immune system47,48 and use a system of nonlinear,
ODEs to describe time course behavior of cells and
other system elements. The first model published
to capture within-host dynamics during a bacterial
infection explored Mtb infection dynamics at the site
of infection,37 and next-generation models included
additional cell types and cytokines that play roles in
the immune response in the lung environment.35,36
To develop these models, we created equations that
were based on known interactions of immune cells
in the lung during infection with Mtb. We used data
from literature to estimate parameter values when
available and performed uncertainty and sensitivity
analysis49 to define the parameter space. In addition,
we validated our models using known experimental
results for gene knockout and depletions from mouse,
NHP, and humans. In this way, we ensured that
the models behaved according to known dynamics.
Once tested, models were used to make predictions
regarding dynamics and data currently not available.
Few other studies have been performed
on modeling within-host dynamics of TB.38,39
Magombedze et al.38 built an ODE system based on
our previously published work but with the emphasis
on analytical results (e.g., bifurcation analysis). Day
et al.39 built a model to understand the environment
in the lung during infection and introduced two
novelties to host–pathogen modeling: first, they
represented macrophages by activation phenotypes
(classically vs alternatively activated macrophages,
CAM vs AAM) and second, they focus on the concept
of switching time (i.e., the time needed to switch
from an AAM-dominated to a CAM-dominated lung
environment during infection). They argued that the
biological relevance of increasing switching times is
that a delay in CAM presence in the lung may be
responsible for Mtb gaining an initial ‘foothold’.
Modeling makes predictions about processes
that are currently not possible to observe experi-
mentally. A key modeling contribution to our under-
standing of TB regards the cytokine IL-10. This is
a cytokine that serves to downregulate the immune
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response, suppressing excessive inflammation during
infection. During mouse deletion and depletion stud-
ies, it was determined that this molecule had no strong
effect on disease outcome of Mtb.50 Our studies sug-
gested something different—a subtle phenotype that
was missed. Our simulations of IL-10 deletion and
depletion showed that the system went from an asymp-
totically stable steady state to a less stable oscillatory
state—one that was easily missed with experimental
approaches. This suggests that IL-10 is an impor-
tant stabilizer of the system that was later confirmed
with experiments performed based on our work.51,52
Another key result made possible by the mathematical
formulation was to study selective deletion of CD8+
T-cell subsets. Models suggested a differential contri-
bution for CD8+ T-cell effectors that are cytotoxic
as compared with those that produce IFN-γ ; it is not
possible to delete one subset or the other in experi-
ments, but this can be performed in a model. We also
predicted the minimum levels of effector memory cells
of each T-cell subset (CD4+ and CD8+) that provide
effective protection following vaccination.36
As useful as these temporal models are in predict-
ing certain aspects of immunity, they cannot recapit-
ulate details of granuloma formation because they do
not include a way to capture spatial structure (Figure
3). It was recognized in the early 1990s that cellular
automata models were a way to capture stochastic,
discrete events occurring in the immune system.53
After the development of object-oriented program-
ming, ABMs appeared and provided more flexibility
in capturing agents (cells, etc.) and their behaviors.54
The first ABM to describe the immune response to a
pathogen was developed for Mtb and specifically to
characterize mechanisms that control granuloma for-
mation and function.31 Next-generation models have
included additional cell types (e.g., effector CD8+
T cells and regulatory T cells), cytokines (e.g., TNF),
and chemokines (e.g., CCL5, CCL10) as data on
those became available.30 By defining simple rules
of interactions between cells (macrophage and effec-
tor T cells), bacteria (Mtb), and environment (a 2-D
grid representing a 2 mm by 2 mm section of lung
tissue), unique spatially specific mechanisms emerge
as important immune control factors in TB infection
(Figure 3a). Here again, model rules were based on
experimental data regarding cell–cell interactions that
were available and the model was tested against cell
depletion and deletion data for humans, primates,
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FIGURE 3 | Individual scale models to understand the role of tumor necrosis factor (TNF) in tuberculosis (TB). (a) 2-D Agent-based model (ABM)
simulation of a granuloma showing baseline solid granuloma and a necrotic TNF−/− granuloma.30 (b) Virtual clinical trial of anti-TNF therapy shows
the number of reactivations per 100 virtual patients using two types of anti-TNF treatments and two different reactivation thresholds.35 (c) Prediction
of a TNF gradient in a granuloma due to secretion and uptake kinetics by different cell types.29
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and mouse systems. Currently, there are no experi-
mental methods available to observe the dynamics of
individual granuloma formation over a long time in
primates and humans. Thus, our models are the first
to look at the dynamics of granuloma formation in
the lung from initial infection onwards.
Cytokines have multiple actions, but one cannot
experimentally separate these effects of an individual
molecule. In a third study, we used the ABM of a
granuloma formation to separate the multiple known
activities of the cytokine TNF (macrophage activa-
tion, regulation of apoptosis, chemokine and cytokine
production, and regulation of cellular recruitment via
transendothelial migration) to study how each con-
tributes, alone and in combination, to granuloma
formation, maintenance, and ultimately pathology.30
Key insights from these ABMs include identifying a
key role in granuloma formation of chemokine dif-
fusion kinetics, macrophage overcrowding within the
granuloma, arrival time of T cells from the LN, as well
as location and the number of T cells within the gran-
uloma. For example, by shortening the arrival time
of effector T cells at the infection site (lung), lower
bacterial loads and clearance could be obtained. This
suggests that a specific vaccine could be effective in
TB. After our initial work, to our knowledge, only one
other study has been published targeting the impact of
spatial effects and inherently stochastic processes on
TB granuloma formation.32 Warrender et al.32 used a
platform called CyCells simulator, obtaining results
very similar to the previously published ABM of
Segovia-Juarez et al.,31 although their focus was on
early events in Mtb infection driving disease outcome.
In addition to modeling the immune response in
the lung, immune responses in LNs have also been
studied. Nearly all of these models are not TB specific,
but do give insights into the DC–T-cell interaction
(cf. Table 2). One of the most useful outputs of
these simulations is a prediction of the number and
dynamics of primed T cells produced in the LN and
available to travel to a site of infection.21
Multiorgan Models
Multiorgan models are needed to capture important
processes such as cellular activation and immune cell
priming that occur in the LN, leading to traffick-
ing of cells back to sites of infection40–42 (Figure 2).
This involves linking models describing individual
physiological compartments together with consider-
ation of scaling and flow between compartments.
Typically, little to no experimental data is available
describing these events. Thus, the models have to be
validated individually and then linked. Multicompart-
mental approaches suggested that delays in either DC
migration to the LN or T-cell trafficking to infec-
tion sites could dramatically alter infection outcomes,
leading to either bacterial clearance or overgrowth if
not regulated properly. A natural progression toward
a next-generation multiorgan model builds into the
ABM formulation some of the mechanisms of T-cell
priming in LNs. A first-time hybrid multiorgan model
couples a discrete/stochastic system to a continu-
ous/deterministic system (manuscript in preparation).
Building a hybrid model is a first step before moving
on to the final development, which is to link two organ
ABMs (Figure 2). This remains an open problem.
Multiscale Models and Tuneable Resolution
We have published multiscale mathematical mod-
els addressing the effects of host genetics and
demographic factors on TB epidemics,4 and investi-
gated how multiple polymorphisms interact to deter-
mine individual susceptibility to TB.5 Fallahi-Sichani
et al.29 recently developed a multiscale PDE granu-
loma model that includes TNF/TNF receptor binding
and trafficking processes (Figure 3c). This model rep-
resents a first attempt to quantify impact of immune
cell organization on TNF bioavailability within the
granuloma—data that are presently not obtainable in
vivo or in vitro. Organization of immune cells and
molecular level mechanisms (i.e., TNF/TNF receptor
binding) are identified as important factors regulating
bioavailability. One great advantage of this modeling
approach is that the action of several known drugs
could be tested on a molecular level basis, and not
simply at a phenomenological level as in the study by
Marino et al.35 (Figure 3b). Indeed, we are currently
extending this work by incorporating molecular scale
TNF dynamics into a multiscale tuneable-resolution
ABM of the granuloma to learn how TNF dynam-
ics influence granuloma development at each scale
(submitted).
CONCLUSION
Despite all of the experimental and theoretical work,
TB remains the main killer by infectious disease in
the world. Specific open questions are as basic as how
treatment works and what factors are important for
vaccine development. A systems biology approach,
integrating both modeling and experimental aspects,
is essential; however, challenges remain in both areas.
Development of multiscale, multicompartment models
with tuneable resolution requires significant effort
in model development and validation. Experimental
techniques are needed that allow, e.g., measuring in
vivo and real-time cell and bacterial counts during
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infection progression, or tracking cells moving within
a single organ (lung) or, more elusively, between
organs over long time and large space. Collaboration
between experimental and modeling colleagues is
crucial to achieve our goal of unraveling mechanisms
of TB infection, prevention, treatment, and cure.
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